BioSight
Companies
Upstream Bio, Inc. logo

UPB

NASDAQWALTHAM, MA
Upstream Bio, Inc.

Upstream Bio develops verekitug, a biologic drug candidate currently in clinical testing for inflammatory airway diseases including severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream is in early-to-mid stage development, having initiated clinical trials for verekitug and working toward FDA approval for commercial use. The company relies on third-party manufacturers to produce verekitug and plans to commercialize the drug if regulatory approval is obtained.

Price history not yet available for UPB.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar